Alx Oncology Holdings (ALXO) Net Equity Issued and Repurchased (2019 - 2026)

Alx Oncology Holdings (ALXO) has 5 years of Net Equity Issued and Repurchased data on file, last reported at $11000.0 in Q1 2026.

• For the quarter ending Q1 2026, Net Equity Issued and Repurchased fell 97.04% year-over-year to $11000.0; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (down 95.09% YoY), and the FY2025 full-year result was $1.7 million, down 94.31% from the prior year.
• Net Equity Issued and Repurchased declined to $11000.0 in Q1 2026, from $1.3 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $26.2 million in Q2 2024 to a low of $11000.0 in Q1 2026.
• A 3-year average of $4.5 million and a median of $372000.0 in 2025 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased surged 266.57% in 2025 and slumped 97.04% in 2026, its largest moves.
• Tracing ALXO's Net Equity Issued and Repurchased over 3 years: stood at $359000.0 in 2024, then surged by 266.57% to $1.3 million in 2025, then slumped by 99.16% to $11000.0 in 2026.
• Business Quant data shows ALXO's Net Equity Issued and Repurchased at $11000.0 in Q1 2026, $1.3 million in Q4 2025, and $372000.0 in Q1 2025.